Flow Cytometry for Lymphoma and Leukemia Characterization

Flow cytometry evaluates markers on viable cells and can help characterize selected lymphoid or blood-cell populations when the right fresh sample is available.

Cells are labeled with antibodies and passed through an instrument that measures marker expression and physical characteristics. Sample site, cell viability, cellularity, transport time, prior treatment, and the laboratory panel all matter.

For selected lymphoma or leukemia cases, flow cytometry may support lineage assignment, identify an abnormal population, add prognostic information, or direct further testing. It is interpreted with cytology, CBC, histopathology, and clinical findings.

Its value is highest when the result answers a defined question and would change diagnosis, staging, treatment, anesthesia, supportive care, or the recheck plan. Testing without a decision pathway can add cost or uncertainty without helping the patient.

The veterinary team selects timing, sample type, preparation, laboratory or imaging method, and repetition interval for the individual patient. Ask how this result will be interpreted alongside examination findings, pathology, prior results, medicines, and current symptoms.

Clinical laboratory guidance and published studies support defined uses, but performance varies by species, sample, tumor subtype, panel, and prevalence. A negative or equivocal result does not universally exclude lymphoma or leukemia.

The main risks come from collecting the blood, fluid, or tissue aspirate and from loss of diagnostic yield if too few viable cells arrive. Starting steroids or chemotherapy before sampling can alter some results and should be discussed first.

A normal result cannot rule out every tumor or complication, and an abnormal result does not by itself identify the cause. Collection quality, timing, prior treatment, sedation, and laboratory or operator variation can affect interpretation.